原始出處紀錄
決策級主要結果 (Topline)
Neurogene 公布 NGN-401 用於 Rett 症候群的 Phase 1/2 期正面數據
該 8-K 文件揭露 Neurogene 發布其 NGN-401 基因療法在 Rett 症候群女性患者 Phase 1/2 期試驗的最新正面臨床數據。公司亦於同日舉辦電話會議，並提供企業簡報。文件中未提及未來的法規里程碑日期。
關鍵事實
來源摘錄
ngne-20260629 0001404644 FALSE 0001404644 2024-03-18 2024-03-18 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 29, 2026 Neurogene Inc. (Exact name of registrant as specified in its charter) Delaware 001-36327 98-0542593 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.) 535 W 24 th Street , 5 th Floor New York , NY 10011 (Address of principal executive offices, including zip code) Registrant's telephone number, including area code: ( 877 ) 237-5020 N/A (Former Name or Former Address, if Changed Since Last Report) Check the appropriate bo